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ABSTRACT  
 
Objectives To determine the risk of Type 2 diabetes (T2D) and cardiovascular diseases in 
psoriatic arthritis (PsA) patients compared to the general population and patients with 
psoriasis. 
 
Methods Incident PsA patients aged 18-89 years were identified in the UK Clinical Practice 
Research Datalink between 1998 and 2014 and were matched (1:4 ratio) to a general 
population cohort and psoriasis cohort. The incidence of T2D, cerebrovascular disease 
(CVD), ischaemic heart disease (IHD) and peripheral vascular disease (PVD) was calculated 
for each study cohort. Conditional Poisson regression was used to calculate adjusted 
Relative Risks (RRadj). 
 
Results We identified 6,783 incident cases of PsA. The risk of T2D was significantly higher in 
the PsA cohort than the general population and psoriasis cohorts (RRadj1.40 (CI951.15-1.70) 
and   RRadj1.53 (CI951.19-1.97) respectively). The incidence of IHD, PVD, and the three 
cardiovascular outcomes combined in the PsA cohort was significantly higher than in the 
general population. No significant differences in risk were observed between the PsA and 
psoriasis cohorts for any cardiovascular outcome. 
 
Conclusion 
The development of T2D in an incident population of PsA is significantly higher than in 
psoriasis alone or a general population, whereas the increased risk of cardiovascular disease 
in PsA and psoriasis is similar.  
 
Keywords: Psoriatic arthritis, Type 2 diabetes, cardiovascular disease, psoriasis, cohort study 
 
Key Messages 
The development of type 2 diabetes is an important comorbidity following onset of psoriatic 
arthritis. 
There is an increased risk of cardiovascular disease in psoriatic arthritis similar to that seen 
in psoriasis.  
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INTRODUCTION  
Psoriatic arthritis (PsA) is a chronic multisystem inflammatory disease reported to affect 10-
40% of individuals with psoriasis [1]. There is strong evidence that patients with rheumatoid 
arthritis (RA) have an increased risk of cardiovascular disease morbidity and mortality, likely 
in part to be linked to inflammation [2], but at present the evidence in relation to PsA as 
opposed to psoriasis alone is less abundant.  
 
The understanding of cardiovascular risk in PsA is complicated by an increased prevalence of 
established cardiovascular risk factors, including the metabolic syndrome (at least three of: 
obesity, hypertension, impaired glucose tolerance and dyslipidaemia) [3, 4] which is also 
associated with an increased risk of developing Type 2 diabetes (T2D). Many of the earlier 
studies of cardiovascular disease focussed on patients with psoriasis [5, 6], with later studies 
looking specifically at PsA [7-10]  and a few separating the PsA population from those with 
psoriasis alone [11, 12]. These have investigated a range of different cardiovascular 
composite endpoints and have varied in terms of their study design, study population, 
outcome definitions, comparator groups and consideration of risk factors.  
 
Although several studies have evaluated the incidence of cardiovascular disease events, 
many have been within all PsA patients and few studies have looked at the risk within a 
cohort of newly diagnosed, incident patients, where the temporal relationship can be better 
determined. Therefore we aimed to calculate the risks of cerebrovascular disease (CVD), 
ischaemic heart disease (IHD), peripheral vascular disease (PVD) and T2D, within a cohort of 
incident PsA patients in the United Kingdom (UK) and compare these with the risks in 
matched cohorts of the general population and patients with psoriasis but no PsA. 
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METHODS 
The UK Clinical Practice Research Datalink (CPRD) contains anonymised medical records for 
~15 million individuals collected within primary care and is generally representative of the 
UK population [13].  
 
A cohort of incident PsA patients aged 18-89 and diagnosed between 1-Jan-1998 and 31-
Dec-2014 were identified in the CPRD. Patients were required to have ≥1 year of up-to-
standard (UTS) data contribution prior to their date of PsA diagnosis (index date). Cases of 
PsA were matched at a 1:4 ratio to two randomly selected cohorts based on their index 
date, year of birth, sex and general practice: the first matched cohort (the general 
population cohort) included patients with no psoriasis, no PsA and no other inflammatory 
arthritis, and the second cohort (the psoriasis cohort) included patients with psoriasis but no 
diagnosis of PsA or other inflammatory arthritis. Patients in the comparator cohorts were 
assigned the index date of the matched case and were required to have ≥1 year of UTS data 
prior to the index date. Patients were followed from the index date until the date they were 
no longer eligible for the cohort or were diagnosed with the outcome of interest. Patients in 
the general population and psoriasis cohorts who developed psoriasis or PsA respectively 
after the index date had their person-time contribution censored the day before the 
diagnosis date.  
 
The outcomes of interest were T2D, CVD, IHD and PVD, identified based on Read codes.  An 
algorithm created and utilised in previous investigations was used to identify patients with 
T2D [14]. A full description of the methods can be found in Online Supplement I. 
 
Ethical approval  
Ethical approval was obtained by the CPRD data provider from a Multicentre Research 
Ethics Committee for all observational studies and the study protocol was approved by the 
CPRD Independent Scientific Advisory Committee (15_154R). No additional approval or 
consent was needed. 
 
Statistical analyses 
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The incidence, per 10,000 person-years, of T2D, CVD, IHD and PVD were calculated for each 
study cohort. For each outcome, conditional Poisson regression was used to calculate crude 
and adjusted relative risks (RR) comparing the risk in the PsA cohort with the risk in the 
general population and psoriasis cohorts. The following covariates were considered for 
adjustment in the model; smoking status, body mass index, a prior history of 
hyperlipidaemia including the issue of a statin prescription, treated hypertension, T2D, 
psoriasis severity on the index date and corticosteroid and non-steroidal anti-inflammatory 
drug (NSAID) prescribing. The final models were adjusted for all significant covariates (p 
<0.05), which was based on their contribution to the model as defined by their contribution 
to the likelihood. Analyses were performed using R 3.3.0 (R Core Team, 2017).  
 
RESULTS 
We identified 6,783 eligible incident cases of PsA, 27,132 matched patients from the general 
population and 27,132 matched psoriasis patients. The median age at PsA diagnosis was 49 
years (IQR 39-59). Table 1 shows the baseline patient characteristics for each cohort. The 
mean duration of follow-up was similar for all cohorts at approximately 5.5 years.  
 
The incidence of T2D was significantly higher in the PsA cohort than both the general 
population and psoriasis cohorts (RRadj 1.40 (CI95 1.15-1.70) and   RRadj 1.53 (CI95 1.19-1.97) 
respectively) (Table 2). The incidence of any of the cardiovascular outcomes combined in 
the PsA cohort was significantly higher than in the general population (RRadj 1.29 (CI95 1.12-
1.48)) but not in the psoriasis cohort (RRadj 1.09 (CI95 0.95-1.24)). The incidence of IHD and 
PVD was significantly higher incidence in the PsA cohort than the general population cohort 
(RRadj 1.27 (CI95 1.05-1.54) and RRadj 1.40 (CI95 1.02-1.92)). No significant differences in risk 
were observed between the PsA and psoriasis cohorts for any of the cardiovascular 
outcomes (Table 2). The median age at incident outcomes was similar for all three cohorts, 
ranging from approximately 60 years for T2D to 69 years for CVD (Supplementary Table 1). 
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DISCUSSION 
This population-based study identified a 50% increase and 40% increased risk of T2D among 
an incident cohort of PsA patients compared to patients with psoriasis and those in the 
general population respectively. There was a 29% increase in risk of the combined 
cardiovascular diseases, a 27% increase in the risk of IHD and a 40% increase in risk of PVD 
in PsA compared with the general population after taking into account other potential risk 
factors, but no increase in any of the cardiovascular outcomes compared to the psoriasis 
population.  
 
The incidence rates and increased risks observed for T2D in our study using data from the 
CPRD are consistent with those reported elsewhere [12, 15, 16].  A systematic review and 
meta-analysis of observational studies investigating the association between psoriasis, PsA 
and T2D reported the highest risk for patients with PsA and a ‘dose effect’ in the risk for 
patients with psoriasis, with those with severe psoriasis having the highest risk [17].  
Dubreuil et al reported an increased incidence of diabetes in PsA, psoriasis and rheumatoid 
arthritis compared to cohorts without the corresponding condition in The Health 
improvement Network (THIN), a similar database to the CPRD [15].  Unlike rheumatoid 
arthritis the increased risk of diabetes in PsA and psoriasis was not fully accounted by life-
style risk factors, leading the authors to postulate that immune-mediated inflammatory 
processes specific to psoriatic conditions may exert an effect [15].  
 
Herein we have found that the risk of T2D is 50% higher in PsA than in a matched cohort of 
patients with psoriasis. We adjusted for possible co-variates including BMI, psoriasis severity 
and corticosteroid and NSAID prescribing all of which could conceivably account for the 
findings, although cannot exclude residual confounding. It is possible that the additional 
inflammatory burden associated with arthritis in combination with higher levels of obesity 
contribute to the higher risk observed in the PsA cohort than the psoriasis cohort, although 
we were unable to measure inflammatory markers such as C-reactive protein.  A study from 
the University of Toronto PsA clinic has also reported an association between higher levels 
of inflammation and PsA disease activity and the risk of diabetes [18]. Similarly, the 
metabolic syndrome and insulin resistance in PsA has been associated with severity of the 
underlying disease [19]. Other possibilities to explain the increased risk of T2D in PsA 
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compared to psoriasis alone include unidentified genetic factors unique to PsA and T2D, the 
contribution from diet and the microbiome, and the influence of exercise.  We were unable 
to adjust for levels of exercise that are likely to be lower in PsA than controls and may 
influence body composition and insulin receptor levels in favour of development of 
diabetes.   
 
The lack of a significant increase in risk of cardiovascular comorbidities in patients with PsA 
compared to those with psoriasis is consistent with another study using the CPRD [12] and a 
study of patients from the University of Toronto PsA clinic and psoriasis cohort [11].  
However, in both studies the specific cardiovascular endpoints were different and in the 
Toronto study prevalence rather than incidence of cardiovascular disease was calculated. 
The presence of an increased risk when compared to the general population looking at the 
three cardiovascular outcomes (CVD, IHD, PVD) combined, but only an increased risk for IHD 
and PVD when looking at them separately may partly be due to a lack of statistical power.   
 
The population-based nature and large number of PsA patients included in our study are 
both strengths, as were the use of validated codes to identify psoriasis and PsA and the 
inclusion of both a psoriasis and general-population matched comparator group. The 
inclusion of only incident PsA patients was an advantage for looking at temporal 
relationships, but will have had an impact of the duration of follow-up available and may 
have resulted in some patients having insufficient follow-up time (mean duration 5.5 years) 
after their PsA diagnosis to develop the specific cardiovascular outcomes of interest. There 
may be some degree of both detection and referral bias, with PsA patients being more likely 
to visit their healthcare professionals regularly and therefore more likely to undergo 
investigations and receive a comorbidity diagnosis. Also, the absence of data on tumour 
necrosis factor-alpha inhibitor (TNFi) therapy and PsA disease activity in the CPRD meant it 
was not possible to explore the effect of TNFi therapy and disease activity on the incidence 
of T2D and cardiovascular disease.  
 
The results of this study have demonstrated an increased risk of T2D, IHD and PVD amongst 
patients with PsA compared with the general population, after adjustment for traditional 
risk factors. These results support the proposal in existing clinical guidelines [20, 21] that in 
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order to reduce cardiovascular risk in patients with PsA it is important to treat inflammatory 
disease as well as screen and treat traditional risk factors early in the disease course.  
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Table 1 
 Baseline characteristics of the PsA, psoriasis and general population cohorts  
 PsA Psoriasis  
cohort 
General 
population cohort 
 N % N % N % 
N 6,783  27,132  27,132  
Sex (% male) 3,327 49.05 13,308 49.05 13,308 49.05 
Median age*, years (IQR) 49 (39-59) 49 (39-59) 49 (39-59) 
Mean follow-up post index, years (SD) 5.8 (4.1) 5.5 (4.1) 5.5 (4.1) 
Mean duration of psoriasis,* years (SD) 11.3 (10.9) 11.8 (10.6) --- --- 
Body mass index†       
 <25.0 869 (12.8) 4,190 (15.4) 4,149 (15.3) 
 25.0-29.9 1,226 (18.1) 4,511 (16.6) 4,257 (15.7) 
 30.0-34.9 844 (12.4) 2,602 (9.6) 2,254 (8.3) 
 ≥35.0 641 (9.5) 1,746 (6.4) 1,252 (4.6) 
 Unknown 3,203 (47.2) 14,083 (51.9) 15,220 (56.1) 
Smoking status†       
 Non-smoker 3,059 (45.1) 11,001 (40.6) 13,533 (49.9) 
 Current smoker 1,605 (23.7) 8,199 (30.2) 6,509 (24.0) 
 Ex-smoker 2,084 (30.7) 7,480 (27.6) 6,067 (22.4) 
 Unknown 35 (0.5) 452 (1.7) 1,023 (3.8) 
Hyperlipidaemia or ≥1 statin prescription‡ 1,044 (15.4) 4,137 (15.2) 3,490 (12.9) 
Treated hypertension‡ 1,928 (28.4) 6,574 (24.2) 5,618 (20.7) 
Type 2 diabetes‡ 414 (6.1) 1500 (5.5) 1160 (4.3) 
Cerebrovascular disease‡ 106 (1.2) 582 (2.2) 454 (1.7) 
Ischaemic heart disease‡ 314 (4.6) 1288 (4.8) 979 (3.6) 
Peripheral vascular disease‡ 65 (1.0) 225 (1.1) 225 (0.8) 
*  on the index date † closest to and within 3 years prior to the index date ‡  ≥1 diagnosis code on or before the 
index date 
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Table 2 
Risk of type 2 diabetes and cardiovascular disease in patients with PsA  
Comorbidity PsA compared with a general population cohort 
(no PsA and no psoriasis) 
PsA compared with a psoriasis cohort  
 
 Unadjusted Adjusted† Unadjusted Adjusted† 
 RR CI95 P RR CI95 P RR CI95 P RR CI95 P 
             
Type 2 diabetes 1.72 1.50-1.97 <0.0001 1.40a 1.15-1.70 0.0007 1.49 1.30-1.70 <0.0001 1.53f 1.19-1.97 0.0009 
             
             
Cardiovascular disease‡ 1.43 1.25-1.63 <0.0001 1.29b 1.12-1.48 0.0005 1.12 0.99-1.28 0.08 1.09g 0.95-1.24 0.23 
             
Cerebrovascular disease 1.40 1.14-1.73 0.0013 1.24c 0.99-1.56 0.06 1.08 0.88-1.32 0.48 1.09h 0.86-1.37 0.48 
Ischaemic heart disease 1.41 1.18-1.69 0.0002 1.27d 1.05-1.54 0.02 1.12 0.93-1.34 0.22 1.06i 0.87-1.28 0.57 
Peripheral vascular disease 1.40 1.02-1.92 0.04 1.40e 1.02-1.92 0.04 1.14 0.84-1.56 0.41 1.14j 0.84-1.56 0.41 
             
‡ including cerebrovascular disease, ischaemic heart disease and peripheral vascular disease 
† The following covariates were considered for adjustment in the model; smoking status, body mass index, a prior history of hyperlipidaemia including the issue of a statin prescription, 
treated hypertension, type 2 diabetes, psoriasis severity on the index date, corticosteroid and NSAID prescribing. The final models were adjusted for all significant covariates (p <0.05) as 
following. a BMI and hypertension; b hypertension; c hypertension and hyperlipidaemia; d hypertension; e No covariates significant and requiring adjustment f BMI, smoking, hypertension and 
NSAID prescribing; gsmoking and hypertension; h smoking, hypertension, hyperlipidaemia and steroid prescribing; i hypertension; j No covariates significant and requiring adjustment 
 
 
